AllPennyStocks.com IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial — Jefferies Sees Neutral To Negative Readthrough To ALNY
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial — Jefferies Sees Neutral To Negative Readthrough To ALNY

Ionis and AstraZeneca already disclosed on July 9 that the late-stage CARDIO-TTRansform missed its primary goal. Full data from the trial was unveiled on Friday.

Other Penny Stock Movers

Fake Players Are Shaping How Games Get Reviewed; This Microcap Just Got Hired to Prove It
Copper's Real Constraint Isn't Demand. It's Ground
Colombian Oil Producer Jumps as Q2 Revenue More Than Doubles
Most Popular
{{ index + 1 }}
AllPennyStocks.com Favorites


Back to Top